Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Bargou, Ralf C.; Leo, Eugen; Zugmaier, Gerhard; Klinger, Matthias; Goebeler, Mariele; Knop, Stefan; Noppeney, Richard; Viardot, Andreas; Heß, Georg; Schüler, Martin; Einsele, Hermann; Brandl, Christian; Wolf, Andreas; Kirchinger, Petra; Klappers, Petra; Schmidt, Margit; Riethmüller, Gert; Reinhardt, Carsten; Baeuerle, Patrick A.; Kufer, Peter

doi:10.1126/science.1158545

articleScienceAug 14, 2008Closed access

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

RCRalf C. Bargou ELEugen Leo GZGerhard Zugmaier MKMatthias Klinger MGMariele Goebeler

Universität Ulm · University of Würzburg · +5 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies…

Citation impact

1,072

total citations

FWCI: 27.57
Percentile: 100%
References: 28

Citations per year

Authors

20

Topics & keywords

Topics

Keywords

Cytotoxic T cell
Antibody
Blinatumomab
Medicine
Cancer
Lymphoma
Bone marrow
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.